(Q38404655)

English

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

scientific article published on 31 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial (English)

1 reference

Europe PubMed Central

2 September 2017

phase III clinical trial

0 references

0 references

0 references

15

1 reference

Europe PubMed Central

2 September 2017

Alexander Eggermont

1

object named as

Alexander M M Eggermont

1 reference

Europe PubMed Central

2 September 2017

Caroline Robert

8

object named as

Caroline Robert

0 references

Jean-Jacques Grob

3

object named as

Jean-Jacques Grob

0 references

Virginia Ferraresi

object named as

Virginia Ferraresi

12

0 references

Paolo Antonio Ascierto

9

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

2 September 2017

Jedd D. Wolchok

5

object named as

Jedd D Wolchok

1 reference

Europe PubMed Central

2 September 2017

21

object named as

Stefan Suciu

1 reference

Europe PubMed Central

2 September 2017

author name string

Vanna Chiarion-Sileni

2

1 reference

Europe PubMed Central

2 September 2017

Reinhard Dummer

4

1 reference

Europe PubMed Central

2 September 2017

Henrik Schmidt

6

1 reference

Europe PubMed Central

2 September 2017

Omid Hamid

7

1 reference

Europe PubMed Central

2 September 2017

Jon M Richards

10

1 reference

Europe PubMed Central

2 September 2017

Céleste Lebbé

11

1 reference

Europe PubMed Central

2 September 2017

Michael Smylie

13

1 reference

Europe PubMed Central

2 September 2017

Jeffrey S Weber

14

1 reference

Europe PubMed Central

2 September 2017

Cyril Konto

16

1 reference

Europe PubMed Central

2 September 2017

Axel Hoos

17

1 reference

Europe PubMed Central

2 September 2017

Veerle de Pril

18

1 reference

Europe PubMed Central

2 September 2017

Ravichandra Karra Gurunath

19

1 reference

Europe PubMed Central

2 September 2017

Gaetan de Schaetzen

20

1 reference

Europe PubMed Central

2 September 2017

Alessandro Testori

22

1 reference

Europe PubMed Central

2 September 2017

publication date

31 March 2015

1 reference

Europe PubMed Central

2 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

2 September 2017

16

1 reference

Europe PubMed Central

2 September 2017

5

1 reference

Europe PubMed Central

2 September 2017

522-530

1 reference

Europe PubMed Central

2 September 2017

Cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970122-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70122-1

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38404655&oldid=2135359336"